

# World Anti-Doping Program

# GUIDELINES TUE ENQUIRIES BY ACCREDITED LABORATORIES

Version 2.0 June 2018

## <u>Objective</u>

The following guideline is the result of continuing efforts to harmonize <u>Laboratory</u> reporting procedures based on the requirements of the *International Standard for* <u>Laboratories</u> (ISL) [1], as well as on the observations and recommendations made by the *WADA* Laboratory Expert Group (LabEG).

This guideline was produced to assist the <u>Laboratories</u> in reporting <u>Presumptive</u> <u>Adverse Analytical Findings (PAAF)</u> exclusively for the S.3. Beta-2 Agonists and S.9. Glucocorticoids drug classes and enquiring with the relevant <u>Testing Authority (TA)</u> and/or <u>Results Management Authority (RMA)</u> about the existence of an approved *Therapeutic Use Exemption (TUE)* before performing confirmation analyses. In accordance with ISL (provision 5.2.4.3.1.1), the decision to confirm the <u>PAAF</u> or report the finding as negative shall be made by the <u>TA</u> and/or <u>or Results Management Authority (RMA)</u> and it shall be retained by the <u>Laboratory</u> as part of the <u>Sample</u> record. The form below is an example of how this requirement may be met. It is recommended that all <u>Laboratories</u> refer to this form when contacting <u>TAs</u> or <u>RMAs</u> for the existence of an approved *TUE*.

### 1. <u>Scope</u>

This guideline follows the rules established in the *World Anti-Doping Agency's (WADA)* ISL [1] and relevant Technical Documents regarding the <u>Analytical Testing</u> of *Samples*. These requirements are still fully applicable and shall be respected. This Guideline contains additional recommendations to facilitate the correspondence between <u>Laboratories</u> and <u>TAs</u> and allows for harmonized recording of such decisions into *ADAMS*. Therefore this guideline also provides guidance on how to maintain traceability in reporting such decisions until such time that specialized reporting modules are available in *ADAMS*.

#### 2. TUE enquiry Requirements

The ISL article 5.2.4.3.1.1 provides the option for Laboratories to contact the relevant <u>TA</u> or <u>RMA</u> to enquire if an approved TUE is on file for a <u>PAAF</u> for beta-2-agonists or glucocorticoids detected in the <u>Initial Testing Procedure</u>. In addition, the <u>Laboratory</u> shall request guidance as to whether, on the basis of the valid *TUE*, the <u>TA</u> wishes the <u>Laboratory</u> to confirm the <u>PAAF</u> or report the finding as "Negative".

It is strongly recommended that the <u>Laboratory</u> utilizes the template form in the Annex to this guideline (or a <u>Laboratory</u> form containing similar descriptive elements) to receive documented and signed evidence of the <u>TA</u>'s instructions.

#### 3. <u>Reporting Requirements</u>

In order to ensure full traceability of the <u>TA</u>'s instructions to confirm the <u>PAAF</u> or to report the *Sample* as Negative for the beta-2 agonist or glucocorticoid <u>PAAF</u>, the following guidance shall be followed in order to incorporate the <u>TA</u>'s authorization into the *ADAM*S record.

It is noted that the *TUE* enquiry form may be uploaded as described below without the need for the <u>TA</u> to "un-match" the *ADAMS* record.

The <u>Laboratory</u> shall record the decision of the <u>TA</u> into ADAMS. Two methods are acceptable to update the *ADAMS* record:

1. Attach the <u>TA</u>-approved *TUE* Enquiry Form to *ADAMS* record:

• Add a statement in the comments section of the *ADAMS* record that clearly identifies that instructions have been received from the <u>TA</u> based on a *TUE* enquiry. For example, enter the statement in the Analysis Details/Explanation/Opinion text field:

"TUE enquiry: refer to attached document under activities tab"

- Upload and attach the signed *TUE* enquiry instructions (in pdf format) through the "Activities" Tab in the *ADAMS* record (see Appendix 2):
  - Select "add activity";
  - Then "browse" under Add Attachment;
  - Select the appropriate pdf document and "open";
  - Add the statement to subject field "TUE Enquiry"; and
  - Click on save.
- Save the *ADAMS* record and submit.
- 2. Add a comment to *ADAMS* record:
  - Add a statement for the comments section of the *ADAMS* record that clearly describes that the <u>TA</u> confirmed the existence of an approved TUE and that the test result may be recorded as Negative. Enter the statement in the Analysis Details/Explanation/Opinion text field:

"**TUE Enquiry**: The Testing Authority confirmed that a proper TUE is on file for [substance] and has authorized the reporting of this sample as "Negative". TUE Enquiry record is on file in the Laboratory". Laboratory Name Laboratory Address (or Letterhead)

## **TUE** Enquiry Form

Date:				
TA or RI	MA:			
Sample	Code:		Lab Code:	
Sport/D	iscipline:			
Mission	Code/Batch ID	)/Event :		

The Laboratory Initial Testing Procedure applied to the sample above identified a P<u>resumptive</u> <u>Adverse Analytical Finding</u> that may fall under an approved *Therapeutic Use Exemption* status within the following drug class identified in the WADA Prohibited List:

Presumptiv	e Analytical Finding:		
Drug Class	S.3 Beta-2 agonists	S	.9 Glucocorticoids
Estimated co	oncentration <sup>1</sup> based on initi	al test:	
_			

<sup>1</sup> the concentration value is a non-confirmed estimation based on a qualitative initial test result.

Name and Title of responsible person:	
Signature:	Date:
	·

#### Section below to be completed by the relevant <u>Results Management Authority</u>:

Please indicate below whether the Laboratory is to perform a confirmatory analysis (based on the existence or absence of a valid TUE for this substance related to the sample identified above)

Do not confirm the <u>Presumptive Adverse Analytical Finding</u> and report sample as Negative.
and report sample as Negative.
(An acceptable TUE, in compliance to the TUE Standard, is on file <sup>2</sup> ).
Confirm the <u>Presumptive <i>Adverse Analytical Finding</i> and report confirmation result.</u>

 $^2$  It is the role of the <u>Testing Authority</u> or <u>Results Management Authority</u> to ensure that the nature of the substance(s) found in the sample is/are commensurate with the prescription as indicated on the granted *TUE*.

Name and title of responsible person:	
Signature of responsible person:	
Organization:	Date:

Please forward this completed form to the [name] Laboratory at

Fax: 123-456-7890 or email scientist@laboratory.org


#### Appendix: TUE Enquiries by Accredited Laboratories Version 2.0 June 2018

Attaching a TUE enquiry form to ADAMS records via the "Activities Tab"

- 1. Note that the ADAMS record will not need to be unmatched by the TA.
- **2.** The <u>Laboratory</u> shall click on the "Activities" Tab in *ADAMS* record of the relevant *Sample* code and then click on the "Add Activity" button.

Analysis Results	1	RMS details	Monitored Substances	Activit	ies(1)		
add activity					Filtered by:	dd-MM-yyyy	
<b>Reference date</b>		Activity		Туре	Posted by	Last updated	+
10-Feb-2017	ĥ	Creation Sub	mitted - Negative	creation	Testlab, Michele	10-Feb-2017 20:12 GMT	+

- **3.** Type the description of the activity in the Subject line (see example below for attaching Test Reports).
- **4.** Under "Add Attachment", click on "Browse" to retrieve and attach the <u>TA</u>'s forwarded *TUE* enquiry document (in pdf format) and click on "Save".



**5.** The *TUE* enquiry will be accessible to the <u>TA</u> and <u>RMA</u>.

		RMS details		onitored stances	Activiti	es(2)					
add activity						Filtere	d by: dd-	-MM-vvvv			
Reference date		Activity			Туре	Posted by		ast updated			+
21-Sep-2017	1	TUE Enquiry		т	User Activity	Boghosian,	Thierry 2	1-Sep-2017 2	20:00	GMT	+
10-Feb-2017	6	Creation Submit	ted - N	legative	creation	Testlab, Mic	hele 1	0-Feb-2017 2	20:12	GMT	+